Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12866948 | 0.84 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1RXRARXRB | |
| SCHEMBL13547936 | 0.81 | CACNA1H (0.37) | — | |
| SCHEMBL12866887 | 0.80 | KCNH2 (0.40) | KCNH2TMEM97SIGMAR1CSNK2A1RXRA | |
| SCHEMBL12881307 | 0.78 | KCNH2 (0.34) | KCNH2TMEM97SIGMAR1CSNK2A1 | |
| SCHEMBL2600029 | 0.78 | RIPK1 (0.41) | — | |
| SCHEMBL11916152 | 0.72 | CES2 (0.34) | CSNK2A1 | |
| SCHEMBL17449698 | 0.71 | FFAR4 (0.39) | — | |
| SCHEMBL24086642 | 0.71 | ESR1 (0.34) | — | |
| SCHEMBL11916146 | 0.70 | KCNQ3 (0.33) | CSNK2A1 | |
| SCHEMBL12866848 | 0.70 | KCNH2 (0.47) | KCNH2TMEM97SIGMAR1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | KCNH2 726/4885TMEM97 1020/4885SIGMAR1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.